A Danish population-based study found that SGLT2 inhibitors are associated with reduced gout risk compared to other diabetes medications, with GLP-1 drugs also showing potential benefit.
Diabetes drugs prevent goutSGLT2 inhibitors reduce gout risk by increasing kidney uric acid excretion — a bonus benefit for diabetes patients who commonly suffer from gout
What the researchers found
SGLT2 inhibitors associated with reduced gout risk compared to other antidiabetic medications in a Danish population-based cohort. GLP-1 peptides also showed potential gout risk reduction.
Why it matters
Gout affects millions of diabetes patients and causes debilitating pain. Drugs that control blood sugar AND reduce gout risk provide dual benefits, informing medication choice for patients with both conditions.
The numbers in context
N=11,047 pairs; 42,201 person-years; HR 0.58 (0.44-0.75); IRD -3.0; SR 0.63 (0.47-0.84); 4.1 vs 7.0/1000 PY
How the study worked
Danish population-based cohort study. SGLT2 inhibitor and GLP-1 RA use compared to other antidiabetic medications for gout incidence.
Who was studied
Danish adults with type 2 diabetes starting SGLT2 inhibitors or GLP-1 receptor agonists
What this study cannot tell us
Observational population study — cannot prove causation. Confounding by indication possible. GLP-1 gout evidence less robust than SGLT2i. Danish population may not generalize to other ethnicities.
How to read the evidence
Moderate evidence: large population-based cohort study with real-world data, but observational design limits causal conclusions.
When this study was published
Published 2021. SGLT2i effects on uric acid and gout continue to be confirmed.
The bigger picture
SGLT2 inhibitors and GLP-1 drugs continue accumulating benefits beyond glucose control — cardiovascular, renal, and now potentially gout protection. This multi-benefit profile strengthens their position as preferred diabetes medications.
Questions still open
- Would SGLT2 inhibitors prevent gout in non-diabetic patients with hyperuricemia?
- Is the gout benefit stronger with specific SGLT2i drugs?
- Does the GLP-1 gout reduction persist in prospective studies?
Common questions
Can diabetes drugs prevent gout?
How do SGLT2 inhibitors reduce uric acid?
Read the original research
Sodium-glucose cotransporter-2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis.
Pharmacoepidemiology and drug safety, 30(10), 1391-1395
Citation
Lund, Lars Christian; Højlund, Mikkel; Henriksen, Daniel Pilsgaard; Hallas, Jesper; Kristensen, Kasper Bruun. (2021). Sodium-glucose cotransporter-2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis.. Pharmacoepidemiology and drug safety, 30(10), 1391-1395. https://doi.org/10.1002/pds.5252